J&J to buy Abiomed in $16.6 billion deal to boost cardiovascular business

[November 01, 2022]  (Reuters) -Johnson & Johnson said on Tuesday it will acquire Abiomed Inc in a deal valued at $16.6 billion to boost the healthcare conglomerate's cardiovascular devices business.

The upfront payment of $380 per share represents a 50.7% premium to Abiomed's last closing price. Shares of Abiomed surged 48% in premarket trade.

Abiomed shareholders will also get a non-tradeable contingent value right entitling the holder to receive up to $35 per share in cash if certain commercial and clinical milestones are achieved.

The transaction broadens J&J's MedTech as a cardiovascular innovator, advancing the standard of care in one of healthcare's largest unmet need, heart failure and recovery, the company said.

The company logo for Johnson & Johnson is displayed to celebrate the 75th anniversary of the company's listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid

The deal comes at a time when J&J is spinning off its consumer health business to focus on its pharmaceuticals and medical devices operations.

(Reporting by Raghav Mahobe and Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.